These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 8821542)

  • 1. Ontogenic aspects of liver and kidney catechol-O-methyltransferase sensitivity to tolcapone.
    Vieira-Coelho MA; Soares-da-Silva P
    Br J Pharmacol; 1996 Feb; 117(3):516-520. PubMed ID: 8821542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase.
    Vieira-Coelho MA; Soares-da-Silva P
    Brain Res; 1999 Mar; 821(1):69-78. PubMed ID: 10064789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catechol-O-methyltransferase: variation in enzyme activity and inhibition by entacapone and tolcapone.
    De Santi C; Giulianotti PC; Pietrabissa A; Mosca F; Pacifici GM
    Eur J Clin Pharmacol; 1998 May; 54(3):215-9. PubMed ID: 9681662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on the tight-binding nature of tolcapone inhibition of soluble and membrane-bound rat brain catechol-O-methyltransferase.
    Borges N; Vieira-Coelho MA; Parada A; Soares-da-Silva P
    J Pharmacol Exp Ther; 1997 Aug; 282(2):812-7. PubMed ID: 9262345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats.
    Napolitano A; Bellini G; Borroni E; Zürcher G; Bonuccelli U
    Parkinsonism Relat Disord; 2003 Jan; 9(3):145-50. PubMed ID: 12573869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of intracerebral 6-nitronoradrenaline, an endogenous catechol-O-methyltransferase (COMT) inhibitor, on striatal dopamine metabolism in anaesthetised rats.
    Huotari M; Passlin M; Nordberg HL; Forsberg M; Kotisaari S; Tuomisto L; Shintani F; Tanaka KF; Reenilä I; Laitinen K; Männistö PT
    J Neurosci Methods; 2001 Aug; 109(1):47-52. PubMed ID: 11489299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minor effect of tolcapone, a catechol-O-methyltransferase inhibitor, on extracellular dopamine levels modified by amphetamine or pargyline: a microdialysis study in anaesthetized rats.
    Tuomainen P; Törnwall M; Männistö PT
    Pharmacol Toxicol; 1996 Jun; 78(6):392-6. PubMed ID: 8829199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catechol-o-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex.
    Tunbridge EM; Bannerman DM; Sharp T; Harrison PJ
    J Neurosci; 2004 Jun; 24(23):5331-5. PubMed ID: 15190105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain catechol-O-methyltransferase (COMT) inhibition by tolcapone counteracts recognition memory deficits in normal and chronic phencyclidine-treated rats and in COMT-Val transgenic mice.
    Detrait ER; Carr GV; Weinberger DR; Lamberty Y
    Behav Pharmacol; 2016 Aug; 27(5):415-21. PubMed ID: 26919286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Comt with tolcapone slows progression of polycystic kidney disease in the more severely affected PKD/Mhm (cy/+) substrain of the Hannover Sprague-Dawley rat.
    Boehn SN; Spahn S; Neudecker S; Keppler A; Bihoreau MT; Kränzlin B; Pandey P; Hoffmann SC; Li L; Torres VE; Gröne HJ; Gretz N
    Nephrol Dial Transplant; 2013 Aug; 28(8):2045-58. PubMed ID: 23543593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucuronidation of entacapone, nitecapone, tolcapone, and some other nitrocatechols by rat liver microsomes.
    Lautala P; Kivimaa M; Salomies H; Elovaara E; Taskinen J
    Pharm Res; 1997 Oct; 14(10):1444-8. PubMed ID: 9358559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects.
    Dingemanse J; Jorga K; Zürcher G; Fotteler B; Sedek G; Nielsen T; van Brummelen P
    Eur J Clin Pharmacol; 1996; 50(1-2):47-55. PubMed ID: 8739811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No change of brain extracellular catecholamine levels after acute catechol-O-methyltransferase inhibition: a microdialysis study in anaesthetized rats.
    Li YH; Wirth T; Huotari M; Laitinen K; MacDonald E; Männistö PT
    Eur J Pharmacol; 1998 Sep; 356(2-3):127-37. PubMed ID: 9774242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opposite effects of tolcapone on amphetamine-disrupted startle gating in low vs. high COMT-expressing rat strains.
    Swerdlow NR; Hines SR; Herrera SD; Weber M; Breier MR
    Pharmacol Biochem Behav; 2013 May; 106():128-31. PubMed ID: 23567203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease.
    Ceravolo R; Piccini P; Bailey DL; Jorga KM; Bryson H; Brooks DJ
    Synapse; 2002 Mar; 43(3):201-7. PubMed ID: 11793426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT Val158Met polymorphism.
    Giakoumaki SG; Roussos P; Bitsios P
    Neuropsychopharmacology; 2008 Dec; 33(13):3058-68. PubMed ID: 18536698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat.
    Forsberg M; Lehtonen M; Heikkinen M; Savolainen J; Järvinen T; Männistö PT
    J Pharmacol Exp Ther; 2003 Feb; 304(2):498-506. PubMed ID: 12538800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Catechol-O-Methyltransferase inhibition and alcohol use disorder: Evaluating the efficacy of tolcapone in ethanol-dependent rats.
    Doyle MR; Dirik S; Martinez AR; Hughes TE; Iyer MR; Sneddon EA; Seo H; Cohen SM; de Guglielmo G
    Neuropharmacology; 2024 Jan; 242():109770. PubMed ID: 37858886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. D1-like dopamine receptor activation and natriuresis by nitrocatechol COMT inhibitors.
    Vieira-Coelho MA; Gomes P; Serrão MP; Soares-da-Silva P
    Kidney Int; 2001 May; 59(5):1683-94. PubMed ID: 11318939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The contribution by monoamine oxidase and catechol-O-methyltransferase to the total-body and pulmonary plasma clearance of catecholamines.
    Friedgen B; Wölfel R; Graefe KH
    Naunyn Schmiedebergs Arch Pharmacol; 1996 Jan; 353(2):193-9. PubMed ID: 8717160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.